Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center
NRG Oncology
Royal Marsden NHS Foundation Trust
VLP Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
University of Chicago
Sanford Health
3B Pharmaceuticals GmbH
Bicara Therapeutics
Leap Therapeutics, Inc.
Providence Health & Services
University of Pittsburgh
Abramson Cancer Center at Penn Medicine
Revolution Medicines, Inc.
Carisma Therapeutics Inc
University of Oxford
Case Comprehensive Cancer Center
Cairo University
Advaxis, Inc.
University College, London
Pfizer
DNAtrix, Inc.
The Netherlands Cancer Institute
Baptist Health South Florida
H. Lee Moffitt Cancer Center and Research Institute
Southern Tohoku BNCT Research Center
University of Kansas Medical Center
Seagen Inc.
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
AbbVie
Celgene
Karyopharm Therapeutics Inc
H. Lee Moffitt Cancer Center and Research Institute
Amgen
Sinocelltech Ltd.
Revolution Medicines, Inc.
University of Zurich
MacroGenics
Northwell Health
Ottawa Hospital Research Institute
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Vanderbilt-Ingram Cancer Center
Takara Bio Inc.
Georgetown University
Novartis